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Pi-class glutathione-S-transferase (GSTP1) located on 
chromosome 11q13 encodes a phase II metabolic 
enzyme that detoxifies reactive electrophilic 
intermediates. GSTP1 plays an important role in 
protecting cells from cytotoxic and carcinogenic agents 
and is expressed in normal tissues at variable levels in 
different cell types. Altered GSTP1 activity and 
expression have been reported in many tumors and this 
is largely due to GSTP1 DNA hypermethylation at the
CpG island in the promoter-5'.  
 
We review the potential novel role of glutathione S-
transferase pi (GSTP1) and its related expression in 
miscellaneous cancers. We focus on the rationale for 
use of molecular assays for the detection of cancer, 
emphasizing the role of the identification of epigenetic 
alterations. Finally, we focus on the potential role f 
GSTP1 in the pathway of prostate cancer, the most 
GSTP1 DNA hypermethylation-related neoplasm 
studied to date.  
Advances in the epigenetic characterization of cancers 
enabled the development of DNA methylation assays 
that may soon be used in diagnostic testing of serum 
and tissue for cancers. Inhibition of aberrant promoter 
methylation could theoretically prevent carcinogenesis. 
Reactive oxygen species that are generated by 
physiologic processes such as cellular respiration, 
exposure to chemical agents, or exposure to ionizing 
radiation may overcome cellular antioxidant defense 
and cause DNA damage (Bostwick et al., 2000). Such 
damage may result in mutations and alteration of 
oncogenes or tumor suppressor genes. The cytosolic 
isoenzyme glutathione S-transferase pi (GSTP1) is an 
important multifunctional detoxifying enzyme within 
the glutathione S-transferase family enzymes that 
inactivates electrophilic carcinogens by conjugation 
with glutathione (Toffoli et al., 1992; Jerónimo et al., 
2001). The regulatory sequence near the GST gene is 
commonly affected by hypermethylation during the 
early stages of carcinogenesis (Lee et al., 1994; Brooks 
et al., 1998; Cairns et al., 2001; Jerónimo et al., 2002; 
Henrique and Jerónimo, 2004). 
Several classes of GST, including alpha, mu, pi, and
theta, were previously found in human tissue. For 
example, compared with benign tissue, there is 
increased expression of GST pi in cancers of the breast, 
colon, stomach, pancreas, bladder, lung, head and neck,
ovary, and cervix, as well as soft tissue sarcoma, 
testicular embryonal carcinoma, meningioma, and 
glioma (Niitsu et al., 1989; Randall et al., 1990; Kantor 
et al., 1991; Satta et al., 1992; Toffoli et al., 1992; 
Green et al., 1993; Inoue et al., 1995; Bentz et al., 
2000; Tratche et al., 2002; Simic et al., 2005; Arai et 
al., 2006). 
However, hypermethylation of the GSTP1 promoter 
has been associated with gene silencing in prostate 
cancer and kidney cancer (Lee et al., 1994; Brooks et 
al., 1998; Cairns et al., 2001; Jerónimo et al., 2002; 
Dulaimi et al., 2004). Similarly, expression of GSTP1 
is lower in invasive pituitary tumors than in 
noninvasive pituitary tumors and methylation status 
correlates with significant downregulation of GSTP1 
expression; the frequency of GSTP1 methylation being 
higher in invasive pituitary tumors with reduced-
GSTP1 expression than in pituitary adenomas with 
normal or high GSTP1 expression. These data indicate 
that GSTP1 inactivation through CpG 
hypermethylation is common in pituitary adenomas and
may contribute to aggressive pituitary tumor behavior 
(Yuan et al., 2008). More recently, a study showed a 
trend of increasing GSTP1 methylation frequency with 
increasing grade of mammary phyllodes tumors. The 
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authors reported that GSTP1 promoter 
hypermethylation was associated with loss of GSTP1 
expression. These results suggest that phyllodes tumors 
segregate into only two groups on the basis of their 
methylation profiles: the benign group and the 
combined borderline/malignant group (Kim et al., 
2009). Other investigators studied the role of 
hypermethylation of the GSTP1 gene promoter region 
in endometrial carcinoma and found that reduced 
GSTP1 expression was associated with myometrial 
invasion potential (Chan et al., 2005).  
Epigenetic alterations: emerging 
molecular markers for cancer detection 
Cancer is a process fuelled both by genetic alterations 
and epigenetic mechanisms. Epigenetics refer to 
changes in gene expression that can be mitotically 
inherited, but are not associated with the changes in the 
coding sequence of the affected genes. In other words, 
epigenetics refer to the inheritance of information 
based on gene expression levels, in contrast to genetics 
that refer to transmission of information based on ge e 
sequence (Esteller et al., 2000). DNA methylation, the 
best understood mechanism in epigenetics, is an 
enzyme-mediated chemical modification that adds 
methyl (-CH3) groups at selected sites on DNA. In 
humans and most mammals, DNA methylation only 
affects the cytosine base (C), when it is followed by a 
guanosine (G). Methylation of the cytosine nucleotide 
residue located within the dinucleotide 5'-CpG-3' is the 
most frequent epigenetic alteration in humans. These 
CpG dinucleotides are not randomly distributed in the
genome. Indeed, there are CpG-rich regions called 
"CpG islands" frequently associated with the 5' 
regulatory regions of genes, including the promoter. 
DNA methylation in the promoter regions is a powerful 
mechanism for the suppression of gene activity. 
DNA methylation analysis: currently 
available methods 
Methylation of CpG islands is of interest for diagnostic 
and prognostic reasons. Methylation of one or both 
alleles of a region can serve as a biomarker of cancer or 
silence gene expression when they are in a promoter 
region (Verma and Srivastava, 2002). Assays for 
methylation are appealing for translational research 
since they can utilize amplification techniques, such as 
methylation-specific polymerase chain reaction (PCR), 
and thereby utilize small amounts of samples. 
Due to its relative simplicity, safety, and sensitivity, 
methylation-specific PCR is the most commonly 
employed method for methylation analysis (Herman et 
al., 1996). 
The conventional methylation-specific PCR (CMSP) 
assay uses two sets of primers specifically designed to 
amplify the methylated or unmethylated sequence, and 
the PCR products are run in a gel (Herman et al., 1996). 
The results of CMSP at a particular DNA region are 
simply reported as methylated or unmethylated, not 
allowing quantitation or identification of partial 
methylation. The CMSP assay is mainly used for 
GSTP1 methylation detection in fluids. For instance, 
GSTP1 methylation in serum of men with localized 
prostate cancer prior to treatment carries a 4.4 fold
increased risk of biochemical recurrence following 
surgery (Bastian et al., 2005). 
The use of fluorescence-based real-time quantitative 
methylation-specific PCR (QMSP) assay improved the 
sensitivity of tumor detection. Continuous monitoring 
of fluorescent signals during the PCR process enabld 
quantification of methylated alleles of a single region 
amongst unmethylated DNA because the fluorescence 
emission of the reporter represents the number of 
generated DNA fragments (Heid et al., 1996). 
GSTP1 hypermethylation: significance 
and incidence related to prostate cancer 
Epigenetic silencing of gluthathione-S-transferase pi 
(GSTP1) is recognized as being a molecular hallmark 
of human prostate cancer. Methylation of CpG islands 
in the promoter of the pi class of glutathione S-
transferase occurs in prostatic intraepithelial neoplasia 
(PIN) and cancer (Gonzalgo et al., 2004). Other 
hypermethylated regions relevant to prostate cancer 
include the retinoic acid receptor beta 2 (Bastian et al., 
2007). These findings in prostate cancer suggest that 
DNA methylation is among the early events in 
tumorigenesis, but it remains to be seen whether DNA 
methylation is a necessary or permissive event in 
tumorigenesis. 
The extensive methylation of deoxycytidine 
nucleotides distributed throughout the 5' "CG island" 
region of GSTP1 is not detected in benign prostatic 
epithelium, but has been detected in intraepithelial 
neoplasia, prostatic adenocarcinoma, and fluids 
(plasma, serum, ejaculate, and urine) of patients wi h
prostate cancer by methylation-specific polymerase 
chain reaction assay, and may be useful as a cancer-
specific molecular biomarker (Lee et al., 1994; Cairns 
et al., 2001; Henrique and Jerónimo, 2004; Crocitto e  
al., 2004; Perry et al., 2006; Hopkins et al., 2007; Cao 
and Yao, 2010). 
Quantitative methylation-specific PCR (QMSP) reveals 
that the epigenetic silencing (loss of expression) of the 
GSTP1 gene is in fact the most common genetic 
alteration in prostate cancer (>90%) and high-grade 
prostatic intraepithelial neoplasia (PIN) (70%) (Lee t 
al., 1994; Brooks et al., 1998; Cairns et al., 2001; 
Harden et al., 2003; Henrique and Jerónimo, 2004) and 
this somatic inactivation ("silencing") of GSTP1 is 
directly associated with promoter methylation (Cairns 
et al., 2001; Jerónimo et al., 2002; Henrique and 
Jerónimo, 2004). Higher levels of GSTP1 promoter 
methylation is associated with the transition from 
prostatic intraepithelial neoplasia (PIN) to carcinoma 
(Henrique et al., 2006). 
During cancer development, GSTP1 does not appear to 
function either as an oncogene or as a tumor suppresso  






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(12) 1183 
gene, since induced GSTP1 expression in prostate 
cancer cell lines failed to suppress cell growth. Instead, 
GSTP1 was proposed to act as a "caretaker" gene. 
When GSTP1 is inactivated, prostate cells appear to 
become more vulnerable to somatic alterations upon 
chronic exposure to genome-damaging stresses as 
oxidants and electrophiles, that are contributed by 
environment and lifestyle (Kinzler and Vogelstein, 
1997; Cairns et al., 2001). 
The significance of absent GSTP1 (GSTP1 silencing) 
in high grade PIN and carcinoma is unclear. It may be 
an epiphenomenon, simply reflecting disruption of the
basal cell layer with neoplastic progression. However, 
Lee et al. considered the likelihood of a more 
fundamental role (Lee et al., 1994). Two studies found 
that a small proportion (3.5-5%) of cases retained 
modest GSTP1 expression in carcinoma (Cookson et 
al., 1997; Moskaluk et al., 1997). Cookson et al. also 
recorded positivity in 1 of 17 cases of high grade PIN 
(Cookson et al., 1997) . Unlike genetic alterations that 
permanently and definitively change DNA sequence, 
promoter methylation is a potentially reversible 
modification. Hence, promoter methylation may be 
amenable to therapeutic intervention aimed at 
reactivating silenced cancer genes. This has important 
implications for chemoprevention because, as 
mentioned above, up to 70% of cases of high-grade 
PIN display GSTP1 promoter methylation (Brooks et 
al., 1998; Cairns et al., 2001; Jerónimo et al., 2002). 
Indeed, recently some authors have investigated the 
effects of green tea polyphenols (GTPs) on GSTP1 re-
expression. They demonstrated that promoter 
demethylation by green tea polyphenols leads to re-
expression of GSTP1 in human prostate cancer cells, 
therefore making green tea polyphenols excellent 
candidates for the chemoprevention of prostate cancer 
(Pandey et al., 2009). 
Some investigators evaluated the impact of androgen 
deprivation therapy on the detection of GSTP1 
hypermethylation in prostate cancer (Kollermann et al., 
2006). In 87% (13/15) of the patients, there was no 
alteration in GSTP1 hypermethylation detection 
(Kollermann et al., 2006) and the authors suggested 
that the change from positive to negative GSTP1 
hypermethylation status in two patients may point to 
partial androgen dependency (Kollermann et al., 2006). 
In addition to the supposed hormonal interaction, other 
possible explanations may be speculated to explain 
why prostate cancer loses GSTP1 hypermethylation 
after prolonged neoadjuvant hormonal therapy. First, 
the lack of GSTP1 hypermethylation may be 
attributable to technical problems (false negative 
results). Furthermore, the possibility that both tumors 
primarily lacked GSTP1 hypermethylation might be 
raised. However, further studies are necessary to assess 
the frequency and extent of hormonal interaction with 
GSTP1 hypermethylation. 
Anti-cancer effect of GSTP1 and future 
prospects 
Increased levels of GST pi may protect human cancer 
cells against cytotoxic drugs. Several antineoplastic 
drugs, particularly reactive electrophilic alkylating 
agents, form conjugates with glutathione spontaneously 
and in GST-catalyzed reactions (Awasthi et al., 1996). 
The expression of particular subclasses of GST protects 
cells from the cytotoxicities of these cancer drugs, and 
overexpression of GST has been implicated in 
antineoplastic drug resistance (Morrow et al., 1998). 
Induction of the enzymes is thought to represent an 
adaptive response to stress, and may be triggered by 
exogenous chemical agents and probably also by 
reactive oxygen metabolites (Hayes and Pulford, 1995). 
GST enzymes have a broad substrate specificity that 
includes substances with known mutagenic properties. 
Elevated serum GST pi has been exploited as a serum 
tumor marker for gastrointestinal cancer (Niitsu et al., 
1989) and non-Hodgkin's lymphoma (Katahira et al., 
2004) as a method of predicting sensitivity to 
chemotherapy. 
Inactivation of GSTP1 in prostate cancer occurs early 
during carcinogenesis, leaving prostate cells with 
inadequate defenses against oxidant and electrophile 
carcinogens. Epigenetic mechanisms (see above) are 
strongly implicated in progression (Rennie and Nelson, 
1998). Unlike genetic alterations, changes in DNA 
methylation are potentially reversible. Thus, 
therapeutic interventions involving reversal of the 
methylation process of several key genes in prostate 
carcinogenesis might improve current therapeutic 
options, thereby enhancing the anti-cancer effect of 
GSTP1 gene in patients "at risk" with high-grade PIN 
or in men with established prostate cancer. Nucleosid -
analogue inhibitors of DNA methyltransferases, such as 
5-aza-2'-deoxycytidine, are able to demethylate DNA 
and restore silenced gene expression. Unfortunately, 
the clinical utility of these compounds has not yet b en 
fully realized, mainly because of their side effects. The 
anti-arrhythmia drug procainamide, a nonnucleoside 
inhibitor of DNA methyltransferases (category of 
enzymes that catalyse DNA methylation during cell 
replication), reversed GSTP1 DNA hypermethylation 
and restorted GSTP1 expression in LNCaP human 
prostate cancer cells propagated in vitro or in vivo as 
xenograft tumors in athymic nude mice (Cairns et al., 
2001). Some investigators tested the potential use of 
procaine, an anesthetic drug related to procainamide. 
Using the MCF-7 breast cancer cell line, they have 
found that procaine produced a 40% reduction in 5-
methylcytosine DNA content as determined by high-
performance capillary electrophoresis and total DNA 
enzyme digestion. Procaine can also demethylate 
densely hypermethylated CpG islands such as those 
located in the promoter region of the RAR beta 2 gene,  
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restoring gene expression of epigenetically silenced 
genes. This property may be explained by binding of 
procaine to CpG-enriched DNA. Finally, procaine also 
has growth-inhibitory effects in these cancer cells, 
causing mitotic arrest (Villar-Garea et al., 2003). Thus, 
procaine and procainamide are promising candidate 
agents for future cancer therapies based on epigenet cs. 
Li et al. reported that GSTP1 was upregulated in the 
stromal compartment of hormone-independent prostate 
cancer, which may contribute to chemoresistance of 
advanced prostate cancer (Morrow et al., 1998). 
Epidemiologic evidence has shown a reduced risk of 
prostate cancer in men consuming selenium, suggestin  
a role for antioxidants in protection against prostate 
carcinogenesis. A systematic review and meta-analysis 
of the literature confirm that selenium intake may 
reduce the risk of prostate cancer (Etminan et al., 
2005). Vitamin E intake also may decrease DNA 
damage and inhibit transformation through its 
antioxidant function. Long-term supplementation with 
alpha-tocopherol substantially reduced prostate cancer 
incidence and mortality in male smokers (Heinonen et 
al., 1998). Therapy directed at the induction or 
preservation of GSTP1 activity in benign prostatic 
epithelium may prevent or delay progression of 
prostatic cancer. 
GSTP1 has a protective role as an antioxidant agent in 
transformation and progression of prostate cancer. The 
interplay between altered or impaired expression of 
GST appears to play a significant role in carcinogenesis 
in the prostate. Inhibition of aberrant promoter 
methylation could be an effective method of 
chemoprevention. 
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